Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | Repurposed HIV and arthritis drugs in the treatment of leukemia

Steven Rosen • 8 Sep 2017
iwNHL 2017
Non-Hodgkin Lymphoma Lefunamide Ritonavir

Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses novel conceptual treatment approaches at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. A novel nucleoside analogue is being developed that targets RNA instead of DNA has shown promising results in the treatment of AML. Drugs are also being repurposed, for example, arthritis drug leflunomide is being trialled in myeloma, and ritonavir, an HIV drug, is being tested to alter the metabolic activity of leukaemia cells.

More from Steven Rosen

2:03
The challenging field of hem-onc therapeutics
Steven Rosen • 21 Sep 2018
1:09
Non-hodgkin lymphoma advances in 2018
Steven Rosen • 21 Sep 2018
1:33
CAR T-cell therapy: on the way to success
Steven Rosen • 21 Sep 2018
1:22
Update on CAR T-cell therapy at the City of Hope
Steven Rosen • 27 Sep 2018

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals